WP
PYXS icon

Woodline Partners’s Pyxis Oncology PYXS Stock Holding History

Woodline Partners’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.58M Buy
+523,999
New +$1M ﹤0.01% 863

Other funds holding PYXS

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Woodline Partners's PYXS Position: Q2 2026 in Review

Woodline Partners opened a new position in Pyxis Oncology (PYXS) in Q2 2026: 523,999 shares worth $1.58M. The stake represents ﹤0.01% of the portfolio and ranks #863 among its holdings.

76 funds tracked by Wall St. Rank hold PYXS as of Q2 2026.

  • Woodline Partners held 523,999 shares of Pyxis Oncology worth $1.58M as of Q2 2026.
  • Pyxis Oncology was a new Woodline Partners position in Q2 2026.
  • Pyxis Oncology made up ﹤0.01% of Woodline Partners's portfolio in Q2 2026, its #863 holding.
  • 76 funds tracked by Wall St. Rank held Pyxis Oncology as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.